Haemonetics Corporation (HAE)

NYQ – Цена в реальном времени. Валюта: USD

54.01

+1.77 (3.39%)

При закрытии: May 12, 2026, 4:00 PM EDT

12.05.2026

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

11.05.2026

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.

10.05.2026

Haemonetics Q4 Earnings Call Highlights

Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.

08.05.2026

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Matson was the top performer as container shipping rates strengthened amid supply chain disruptions and management executed on operational efficiency initiatives. Revolve Group sold off as the online fashion retailer faced softer consumer demand and lower discretionary spending. We added to Haemonetics Corporation following recent share price volatility.

08.05.2026

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

07.05.2026

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07.05.2026

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

24.04.2026

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was published earlier this week in the Journal of Cardiovascular Electrophysiology.

30.03.2026

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) to treat atrial fibrillation.

23.02.2026

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ® Plasma Collection System with Persona ® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.

Haemonetics Corporation (HAE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Haemonetics Corporation (HAE)

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Haemonetics Q4 Earnings Call Highlights

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Видео

No Data

Пресс-релизы

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Haemonetics Q4 Earnings Call Highlights

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Видео

No Data

Пресс-релизы

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Search stocks

Haemonetics Corporation (HAE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Haemonetics Corporation (HAE)

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Haemonetics Q4 Earnings Call Highlights

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Видео

No Data

Пресс-релизы

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Haemonetics Q4 Earnings Call Highlights

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Видео

No Data

Пресс-релизы

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology